Considering the feverish pace of innovation in the field of AI/ML and the inevitable impact on drug development, we outline the documents and guidances that the FDA and EMA have released thus far, comparing and contrasting their areas of focus and concern.
Meeting The Challenge Of Rising API Complexity
Review award-winning AI and vast data that propel a leading predictive retrosynthesis technology and how Lonza tailored its performance to suit the needs of process chemists in preclinical route design.
LIFE SCIENCE LEADER MAGAZINE
Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.